LGVN
Longeveron Inc.
A clinical-stage biotech that turns young adults' bone-marrow stem cells into an injectable therapy, called Lomecel-B, being studied for aging-related conditions like frailty, Alzheimer's disease and a rare childhood heart defect. The company was founded in 2014 and spun out of the University of Miami's stem-cell institute. Its name blends "longevity" with "ever on"—a nod to its mission of helping people live longer, healthier lives.
CUSIP: 54303L104HealthcareUS1 holder
Total Value
$305.0K
Total Shares
86.4K
Net Share Change
+51.4K
Activity
1 buying
Investor
Value
Shares
Weight
Change
